CANY
LAB icon

Caxton Associates (New York)’s Standard BioTools LAB Stock Holding History

Caxton Associates (New York)’s Portfolio LAB Stock Details LAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-27,920
Closed -$371K – 469
2019
Q1 		$371K Buy
+27,920
New +$294K 0.05% 202

Other funds holding LAB

EIP
Easterly Investment Partners Beverly, Massachusetts $1.31B AUM 18.17% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Caxton Associates (New York)'s LAB Position: Q2 2019 in Review

Caxton Associates (New York) sold out of Standard BioTools (LAB) in Q2 2019, closing a stake of 27,920 shares — an estimated $371K sold.

Caxton Associates (New York) first reported a position in LAB in Q1 2019 and held it in 1 quarter. The position peaked at $371K in Q1 2019. 135 funds tracked by Wall St. Rank hold LAB as of Q2 2019.

  • Caxton Associates (New York) reported no remaining Standard BioTools position as of Q2 2019 after selling out during the quarter.
  • Caxton Associates (New York) sold 27,920 Standard BioTools shares in Q2 2019, an estimated $371K.
  • Caxton Associates (New York) first reported a position in Standard BioTools in Q1 2019 and held it in 1 quarter.
  • Caxton Associates (New York)'s Standard BioTools position peaked at $371K in Q1 2019.
  • 135 funds tracked by Wall St. Rank held Standard BioTools as of Q2 2019.

Based on Caxton Associates (New York)'s 13F filing for Q2 2019, filed 14 Aug 2019.